A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

Brignone, Chrystelle; Escudier, Bernard; Grygar, Caroline; Marcu, Manon; Triebel, Frédéric

doi:10.1158/1078-0432.ccr-09-0068

Cited by 192 publications

(118 citation statements)

References 30 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Monoclonal antibodies to LAG-3 are currently in clinical development, with early phase studies demonstrating that a LAG-3 monoclonal antibody is well tolerated with objective responses both as a single agent and in combination with chemotherapy in solid tumors. 99,100 Given the established synergy between LAG-3 and PD-1, both in double knockout mice 101 and with dual blockade in mouse models, 62 this may be an attractive target for combination therapy. A phase I study of the anti-LAG-3 antibody BMS-986016 is currently accruing patients (clinicaltrials.gov identifier: 02061761).…”

Section: Lag-3mentioning

confidence: 99%

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

Vardhana

Younes

2016

Haematologica

View full text Add to dashboard Cite

show abstract

Section: Lag-3mentioning

confidence: 99%

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

Vardhana

Younes

2016

Haematologica

View full text Add to dashboard Cite

show abstract

“…In the last few years, studies have investigated the use of IMP321, a LAG-3-Ig recombinant fusion protein that antagonizes the normal function of LAG-3. These studies were focused on renal cell carcinoma (Brignone et al 2009), metastatic breast carcinoma (Brignone et al 2010) and advanced pancreatic adenocarcinoma (Wang-Gillam et al 2013). All these studies showed promising results regarding the effect of LAG-3 in reducing tumor size.…”

Section: New Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way

Cunha

Marcello

Rocha-Santos

et al. 2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

Immune checkpoint inhibitors are agents that act by inhibiting the mechanisms of immune escape displayed by various cancers. The success of immune checkpoint inhibitors against several tumors has promoted a new treatment strategy in clinical oncology, and this has encouraged physicians to increase the number of patients who receive the immune checkpoint therapy. In the present article, we review the main concepts regarding immune checkpoint mechanisms and how cancer disrupts them to undergo immune escape. In addition, we describe the most essential concepts related to immune checkpoint inhibitors. We critically review the literature on preclinical and clinical studies of the immune checkpoint inhibitors as a treatment option for thyroid cancer, ovarian carcinoma, pancreatic adenocarcinoma, adrenocortical carcinoma and neuroendocrine tumors. We present the challenges and the opportunities of using immune checkpoint inhibitors against these endocrine malignancies, highlighting the breakthroughs and pitfalls that have recently emerged.

show abstract

“…Both renal cell carcinoma and metastatic breast cancer patients saw objective responses when treated with LAG-3 inhibitors and durable disease stabilization [23,24]. Ongoing trials are beginning with a monoclonal antibody to LAG-3; however, no results have been reported.…”

Section: Lag-3 Blockadementioning

confidence: 99%

Immune Checkpoint Blockade: Subjugation of the Masses

Lussier¹,

Appel²,

Johnson³

et al. 2017

Osteosarcoma - Biology, Behavior and Mechanisms

View full text Add to dashboard Cite

Osteosarcoma remains the most common form of bone cancer in adolescents. Standard of care treatment for osteosarcoma includes chemotherapy combined with limb-salvage surgery or amputation. Survival rates for compliant patients are 60-80% for those with localized tumors and 15-30% if the tumor metastasizes or reoccurs. Given the successes of monoclonal antibody blockades in other cancers, clinical trials for applying immunotherapies to osteosarcoma are underway. Antibody blockades reinvigorate T cells to eliminate cancer cells thereby leading to decreased tumor burden and long-term regression. Single monoclonal antibody therapy has shown modest efficacy compared to standard of care.However, treating with only a single antibody can ultimately result in immune evasion by heterogeneous tumors via selection of cells expressing other inhibitory ligands. Hence, combination immunotherapies have yielded the most promising results for eliminating tumors or preventing reoccurrence in other cancer types and will likely be the most efficacious strategy for treating osteosarcoma. Here, we review current immunotherapies for other cancers and their potential application to osteosarcoma.

show abstract

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

Cited by 192 publications

References 30 publications

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way

Immune Checkpoint Blockade: Subjugation of the Masses

Contact Info

Product

Resources

About